US scrutiny over clinical trials in China threatens biotech advantage
Analysts warn that rising US concern about early clinical trials conducted in China could undermine the nation's biopharmaceutical edge.
China holds cost and speed edge
China has established an advantage by conducting clinical trials quickly and at low cost. This capability has helped the country emerge as a major global player in biotechnology.
Washington raises alarms about reliance
US lawmakers and FDA officials have flagged the opaqueness of these processes and urged keeping medical innovations on shore. They are concerned that American pharmaceutical companies rely too heavily on trials located in China.
Firms may double check assets
Legal experts say compliance teams have long been alert to the risks involved. Increased rhetoric from Washington could prompt firms to evaluate China-origin target assets much more carefully before proceeding.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.